These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 15656592

  • 1. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN.
    Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
    [Abstract] [Full Text] [Related]

  • 2. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [Abstract] [Full Text] [Related]

  • 3. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor.
    Doherty DH, Rosendahl MS, Smith DJ, Hughes JM, Chlipala EA, Cox GN.
    Bioconjug Chem; 2005 Jan; 16(5):1291-8. PubMed ID: 16173810
    [Abstract] [Full Text] [Related]

  • 4. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues.
    Spolaore B, Raboni S, Satwekar AA, Grigoletto A, Mero A, Montagner IM, Rosato A, Pasut G, Fontana A.
    Bioconjug Chem; 2016 Nov 16; 27(11):2695-2706. PubMed ID: 27731976
    [Abstract] [Full Text] [Related]

  • 5. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
    Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J, Bordens R.
    J Interferon Cytokine Res; 2001 Dec 16; 21(12):1103-15. PubMed ID: 11798469
    [Abstract] [Full Text] [Related]

  • 6. Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.
    Lee JI, Eisenberg SP, Rosendahl MS, Chlipala EA, Brown JD, Doherty DH, Cox GN.
    J Interferon Cytokine Res; 2013 Dec 16; 33(12):769-77. PubMed ID: 23962003
    [Abstract] [Full Text] [Related]

  • 7. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC.
    Int J Pharm; 2006 Feb 17; 309(1-2):87-93. PubMed ID: 16406701
    [Abstract] [Full Text] [Related]

  • 8. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D.
    Bioconjug Chem; 2006 Feb 17; 17(3):618-30. PubMed ID: 16704199
    [Abstract] [Full Text] [Related]

  • 9. PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice.
    Fam CM, Eisenberg SP, Carlson SJ, Chlipala EA, Cox GN, Rosendahl MS.
    J Interferon Cytokine Res; 2014 Oct 17; 34(10):759-68. PubMed ID: 24841172
    [Abstract] [Full Text] [Related]

  • 10. Conjugation of PolyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate.
    Podobnik B, Helk B, Smilović V, Škrajnar Š, Fidler K, Jevševar S, Godwin A, Williams P.
    Bioconjug Chem; 2015 Mar 18; 26(3):452-9. PubMed ID: 25629733
    [Abstract] [Full Text] [Related]

  • 11. Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues.
    Hu J, Duppatla V, Harth S, Schmitz W, Sebald W.
    Bioconjug Chem; 2010 Oct 20; 21(10):1762-72. PubMed ID: 20886828
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life.
    Shahzadi SK, Qadir MA, Mahmood N, Ahmed M.
    Protein Pept Lett; 2020 Oct 20; 27(3):219-224. PubMed ID: 31612813
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period.
    Peleg-Shulman T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shechter Y.
    J Med Chem; 2004 Sep 23; 47(20):4897-904. PubMed ID: 15369394
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.